Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

639
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
639
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

759
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
759
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

863
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study.

Biomedicines·2025
Same author

Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters.

Diagnostics (Basel, Switzerland)·2025
Same author

The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.

International journal of molecular sciences·2025
Same author

Eustachian Tube Teratoma: A Rare Entity.

Clinical pathology (Thousand Oaks, Ventura County, Calif.)·2023
Same author

Portrait of the Inflammatory Response to Radioiodine Therapy in Female Patients with Differentiated Thyroid Cancer with/without Type 2 Diabetes Mellitus.

Cancers·2023
Same author

Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma.

Journal of personalized medicine·2023

Related Experiment Video

Updated: Jan 5, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K

Cytokines in heart failure.

Adina Elena Stanciu1

  • 1Department of Carcinogenesis and Molecular Biology, Institute of Oncology Bucharest, Bucharest, Romania.

Advances in Clinical Chemistry
|October 28, 2019
PubMed
Summary

Cytokines play a crucial role in heart failure (HF) progression and severity. Understanding these cytokine networks is vital for developing new heart failure treatments and utilizing them as predictive biomarkers.

Keywords:
Anticytokine moleculesBiomarkersCytokinesHeart failure with preserved ejection fractionHeart failure with reduced ejection fractionPrognosisTherapeutic targets

More Related Videos

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes
06:25

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes

Published on: November 11, 2022

3.7K
Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.0K

Related Experiment Videos

Last Updated: Jan 5, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K
A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes
06:25

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes

Published on: November 11, 2022

3.7K
Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.0K

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Heart failure (HF) progression involves structural and functional changes preceding clinical symptoms.
  • Numerous cytokines from cardiac and non-cardiac tissues are implicated in HF.
  • Circulating cytokine levels correlate with HF development and severity.

Purpose of the Study:

  • To discuss the pathophysiological roles of cytokines in HF.
  • To explore the utility of cytokines as predictive biomarkers for HF.
  • To highlight the need for understanding cytokine networks in distinct HF phenotypes for new therapies.

Main Methods:

  • Review of intracardiac and extracardiac cytokine origins in HF.
  • Analysis of cytokine modulation of inflammation, myocyte stress, injury, apoptosis, fibroblast activation, and extracellular matrix remodeling.
  • Discussion of clinical considerations for cytokine use as prognostic biomarkers and therapeutic targets.

Main Results:

  • Cytokines are key mediators in HF pathogenesis, influencing inflammation and cardiac remodeling.
  • Cytokine levels serve as important predictive biomarkers for HF progression and severity.
  • Distinct cytokine networks contribute to different HF phenotypes, such as HF with reduced or preserved ejection fraction.

Conclusions:

  • A comprehensive understanding of the cytokine network is essential for advancing HF treatment strategies.
  • Cytokines hold significant potential as both prognostic biomarkers and therapeutic targets in managing heart failure.
  • Further research into cytokine-mediated mechanisms is crucial for personalized HF management.